Melanoma: Cameron JD

Folberg R, Salomao D, Grossniklaus HE, Proia AD, Rao NA, Cameron JD, Anonymous00355. · Department of Ophthalmology at the University of Illinois at Chicago, 60612, USA. · Hum Pathol. · Pubmed #12612878 No free full text.

This publication has no abstract.

Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Anonymous00118. · Division of Hematology, College of Medicine, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA. · Mayo Clin Proc. · Pubmed #17418079 links to  free full text

Abstract: Critical to the clinical management of a patient with malignant melanoma is an understanding of its natural history. As with most malignant disorders, prognosis is highly dependent on the clinical stage (extent of tumor burden) at the time of diagnosis. The patient's clinical stage at diagnosis dictates selection of therapy. We review the state of the art in melanoma staging, prognosis, and therapy. Substantial progress has been made in this regard during the past 2 decades. This progress is primarily reflected in the development of sentinel lymph node biopsies as a means of reducing the morbidity associated with regional lymph node dissection, increased understanding of the role of neoangiogenesis in the natural history of melanoma and its potential as a treatment target, and emergence of innovative multimodal therapeutic strategies, resulting in significant objective response rates in a disease commonly believed to be drug resistant. Although much work remains to be done to improve the survival of patients with melanoma, clinically meaningful results seem within reach.

Markovic SN, Erickson LA, Rao RD, Weenig RH, Pockaj BA, Bardia A, Vachon CM, Schild SE, McWilliams RR, Hand JL, Laman SD, Kottschade LA, Maples WJ, Pittelkow MR, Pulido JS, Cameron JD, Creagan ET, Anonymous00215. · Division of Hematology, Mayo Clinic College of Medicine, 200 First St SW, Rochester, MN 55905, USA. · Mayo Clin Proc. · Pubmed #17352373 links to  free full text

Abstract: Malignant melanoma is an aggressive, therapy-resistant malignancy of melanocytes. The incidence of melanoma has been steadily increasing worldwide, resulting in an increasing public health problem. Exposure to solar UV radiation, fair skin, dysplastic nevi syndrome, and a family history of melanoma are major risk factors for melanoma development. The interactions between genetic and environmental risk factors that promote melanomagenesis are currently the subject of ongoing research. Avoidance of UV radiation and surveillance of high-risk patients have the potential to reduce the population burden of melanoma. Biopsies of the primary tumor and sampling of draining lymph nodes are required for optimal diagnosis and staging. Several clinically relevant pathologic subtypes have been identified and need to be recognized. Therapy for early disease is predominantly surgical, with a minor benefit noted with the use of adjuvant therapy. Management of systemic melanoma is a challenge because of a paucity of active treatment modalities. In the first part of this 2-part review, we discuss epidemiology, risk factors, screening, prevention, and diagnosis of malignant melanoma. Part 2 (which will appear in the April 2007 issue) will review melanoma staging, prognosis, and treatment.

Faia LJ, Pulido JS, Donaldson MJ, Salomão DR, Cameron JD, Mullan B, Gunduz K. · Department of Ophthalmology,, Mayo Clinic, Rochester, Minnesota, USA. · Retina. · Pubmed #18463523 No free full text.

Abstract: BACKGROUND: To investigate the correlation between the clinical and light microscopic features of choroidal melanoma with combined PET/CT findings. METHODS: This is a retrospective interventional case series of 14 patients with choroidal melanoma referred to the vitreoretinal service at the Mayo Clinic, Rochester, MN. All underwent preoperative combined PET/CT scanning and enucleation. Standardized uptake values (SUV) were correlated with the clinical and light microscopic features of the choroidal melanomas. RESULTS: All 14 eyes showed uptake. The mean patient age was 62 years (SD 12.5 years). The mean tumor thickness was 9.3 mm (range 3-23 mm). Histopathology showed choroidal melanoma in all with the following cell types: 6 mixed cell type, 7 spindle cell type, and 1 epithelioid cell type. The average of the SUV means was 3.7 (range 1.7-12.8). The individual SUV means were correlated with lesion thickness (r = 0.85; P < 0.01) and largest tumor basal diameter (r = 0.65; P = 0.01). Melanomas with focal necrosis (P = 0.03) and of the mixed cell type (P < 0.01) appeared to have higher SUV means. CONCLUSIONS: The majority of the choroidal melanomas had low to medium mean SUVs. Lesion size accounted for a significant portion of the variation, though nonspecific necrosis and cell type were also associated with higher SUV means.